[go: up one dir, main page]

NO20072631L - Kreftbehandlingsmetode - Google Patents

Kreftbehandlingsmetode

Info

Publication number
NO20072631L
NO20072631L NO20072631A NO20072631A NO20072631L NO 20072631 L NO20072631 L NO 20072631L NO 20072631 A NO20072631 A NO 20072631A NO 20072631 A NO20072631 A NO 20072631A NO 20072631 L NO20072631 L NO 20072631L
Authority
NO
Norway
Prior art keywords
treatment method
cancer treatment
administering
breast cancer
brain
Prior art date
Application number
NO20072631A
Other languages
English (en)
Inventor
Stephen Rubin
Original Assignee
Smithkline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36588668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072631(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Cork Ltd filed Critical Smithkline Beecham Cork Ltd
Publication of NO20072631L publication Critical patent/NO20072631L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Beskrevet her er en metode for behandling av brystkreft som har metastasert til hjernen hos et pattedyr ved administrering av 4-kinazolinaminer og farmasøytiske preparater inneholdende samme. Spesielt angår metoden metoder for behandling av brystkreft-hjernemetastaser som ovenittrykker erbB2 ved administrering avN-{3-klor-4-[(3-fluorbenzyl)oksy]fenyl}-6-[5-({[2-(metansulfonyl) etyl]amino}metyl)-2-furyl]-4-kinazolinamin og salter og solvater derav.
NO20072631A 2004-12-17 2007-05-22 Kreftbehandlingsmetode NO20072631L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63705204P 2004-12-17 2004-12-17
PCT/US2005/046350 WO2006066267A2 (en) 2004-12-17 2005-12-16 Cancer treatment method

Publications (1)

Publication Number Publication Date
NO20072631L true NO20072631L (no) 2007-07-02

Family

ID=36588668

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072631A NO20072631L (no) 2004-12-17 2007-05-22 Kreftbehandlingsmetode

Country Status (14)

Country Link
US (2) US20080306097A1 (no)
EP (1) EP1824492B1 (no)
JP (1) JP5291345B2 (no)
KR (1) KR20070107004A (no)
CN (1) CN101083995A (no)
AU (1) AU2005316238B2 (no)
ES (1) ES2426007T3 (no)
IL (1) IL183059A0 (no)
MX (1) MX2007006043A (no)
NO (1) NO20072631L (no)
NZ (1) NZ555462A (no)
RU (1) RU2007119432A (no)
WO (1) WO2006066267A2 (no)
ZA (1) ZA200705059B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7810677B2 (en) 2004-12-04 2010-10-12 Medical Instill Technologies, Inc. One-way valve and apparatus and method of using the valve
EP1906185A1 (en) * 2006-09-26 2008-04-02 ProteoSys AG Use of at least one isoform of progesterone receptor membrane component 1 (PGRMC1)
US8252805B2 (en) 2008-05-07 2012-08-28 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
EP2158912A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158913A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
MX2011009498A (es) 2009-03-11 2011-10-14 Ardea Biosciences Inc Combinaciones farmaceuticas que comprenden rdea119/bay 869766 para el tratamiento de canceres especificos.
CN102146075B (zh) * 2010-02-06 2014-04-02 浙江九洲药业股份有限公司 一种喹唑啉化合物的制备方法
AU2011232219B2 (en) 2010-03-23 2016-02-04 Scinopharm Taiwan, Ltd. Process and intermediates for preparing lapatinib
US8710221B2 (en) 2010-03-23 2014-04-29 Scinopharm Taiwan, Ltd. Process and intermediates for preparing lapatinib
CN102344445B (zh) * 2010-07-23 2015-11-25 岑均达 光学纯喹唑啉类化合物
CN102344444B (zh) * 2010-07-23 2015-07-01 岑均达 光学纯喹唑啉类化合物
CN102321076B (zh) * 2011-07-07 2013-08-21 中国科学技术大学 拉帕替尼中间体及其类似物的制备方法
CZ2012712A3 (cs) 2012-10-17 2014-04-30 Zentiva, K.S. Nový způsob výroby klíčového intermediátu výroby lapatinibu
CN106632276B (zh) * 2015-10-28 2021-06-15 上海天慈生物谷生物工程有限公司 一种治疗乳腺癌药物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9800569D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
WO2002056912A2 (en) * 2001-01-16 2002-07-25 Glaxo Group Limited Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
CA2569139A1 (en) * 2004-06-04 2005-12-22 Smithkline Beecham (Cork) Limited Lapatinib with letrozole for use in a treatment of breast cancer

Also Published As

Publication number Publication date
EP1824492A4 (en) 2009-10-28
AU2005316238A1 (en) 2006-06-22
KR20070107004A (ko) 2007-11-06
EP1824492A2 (en) 2007-08-29
IL183059A0 (en) 2007-10-31
ZA200705059B (en) 2009-09-30
ES2426007T3 (es) 2013-10-18
NZ555462A (en) 2009-03-31
CN101083995A (zh) 2007-12-05
WO2006066267A3 (en) 2006-12-14
JP5291345B2 (ja) 2013-09-18
AU2005316238B2 (en) 2009-05-07
RU2007119432A (ru) 2009-01-27
JP2008524258A (ja) 2008-07-10
WO2006066267A2 (en) 2006-06-22
MX2007006043A (es) 2007-06-13
US20080306097A1 (en) 2008-12-11
EP1824492B1 (en) 2013-07-10
US20150283139A1 (en) 2015-10-08

Similar Documents

Publication Publication Date Title
NO20072631L (no) Kreftbehandlingsmetode
EA200801041A1 (ru) Ингибиторы мек и способы их применения
MX2025001995A (es) Compuesto heterociclico, procedimiento para prepararlo y uso farmaceutico del mismo
IN2014KN02886A (no)
IL199403A0 (en) 4-{4-[({3-tert-butyl-1-[3-(hydroxymethyl)phenyl]-1h-pyrazol-5-yl}carbamoyl)-amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide as well as prodrugs and salts thereof for the treatment of cancer
ATE493418T1 (de) Dihydrofuropyrimidine als akt- proteinkinaseinhibitoren
DK2054418T3 (da) Dihydrothieno-pyrimidiner som AKT-proteinkinase-inhibitorer
NZ700761A (en) Salt form of a human histone methyltransferase ezh2 inhibitor
JOP20210319A1 (ar) مركبات بيروليدين
RU2010144637A (ru) Замещенные гамма-лактамы в качестве терапевтических агентов
MY206327A (en) Formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile
MX2023001468A (es) Tratamiento de cancer de prostata.
PH12022550441A1 (en) Azaheteroaryl compound and application thereof
MX2021003686A (es) Medicamento para el tratamiento de la tos cronica.
EA201992744A1 (ru) Фармацевтические композиции n-(2-(2-(диметиламино)этокси)-4-метокси-5-((4-(1-метил-1h-индол-3-ил)пиримидин-2-ил)амино)фенил)акриламида и его солей
NO20066079L (no) Behandlingsmetode for cancer
EA201991570A1 (ru) Амидные соединения и их применение
EA202192757A1 (ru) Способ лечения опухолей
EA200901062A1 (ru) Использование ингибиторов растворимой эпоксидгидролазы для предотвращения и лечения метаболического синдрома и соответствующих расстройств
NO20066077L (no) Behandlingsmetode for cancer
DE602005020113D1 (de) Verfahren zur behandlung von akuten rhinosinusitis
MX2024015882A (es) Derivados de 3-(sulfonil o sulfonimidoil)prop-2-en-1-il]-2-oxo-1,2-dihidropiridina-3-carboxamida
ZA200609220B (en) Method of treating dry eye disorders and uveitis
MX2022001159A (es) Nueva formulacion farmaceutica.
MX2012002910A (es) Composiciones de n-bencil-3-(4-clorofenil)-2-[metil-[2-oxo-2-(3,4, 5-trietoxifenil)acetil]amino]-n-[3-(4-piridil)-1-[2-(4-piridil)et il]propil]propanamida y usos de las misma.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application